Pharmiweb.com RSS Feed Pharmiweb.com RSS Feeds

Pharmiweb.com RSS Feed PharmiWeb Candidate Blog

Pharmiweb.com RSS Feed PharmiWeb Client Blog

Advertising

Press Releases

271 Press Releases
DateTitleCompany
13 Sep 11 Teva Announces Additional Investment in CureTech Teva Pharmaceutical Industries Ltd.,
Published by
Business Wire
29 Aug 11 Teva Announces Court Adopts All Relevant Teva Claim Construction Interpretations in Copaxone® Patent Infringement Case against Sandoz/Momenta and Mylan/Natco; Court Denies Mylan’s Summary Judgment Motion of Invalidity Teva Pharmaceutical Industries Ltd.,
Published by
Business Wire
08 Aug 11 Teva Receives FDA Acceptance of Its New Drug Application for BDP Nasal HFA for the Treatment of Allergic Rhinitis Teva Pharmaceutical Industries Ltd.,
Published by
Business Wire
02 Aug 11 Teva Receives European Marketing Authorization for ZOELY™ Oral Contraceptive Teva Pharmaceutical Industries Ltd.,
Published by
Business Wire
01 Aug 11 Results of Phase III BRAVO Trial Reinforce Unique Profile of Laquinimod for Multiple Sclerosis Treatment Teva Pharmaceutical Industries Ltd.,
Published by
Business Wire
29 Jul 11 Teva Announces Launch of Camrese™ the Authorized Generic of Seasonique ® Teva Pharmaceutical Industries Ltd.,
Published by
Business Wire
14 Jul 11 Teva Completes Acquisition of Taiyo, the Third Largest Generics Company in Japan Teva Pharmaceutical Industries Ltd.,
Published by
Business Wire
23 Jun 11 Teva Comments on Supreme Court Decision Teva Pharmaceutical Industries Ltd.,
Published by
Business Wire
14 Jun 11 Teva and Cephalon Receive FTC Request for Additional Information Teva Pharmaceutical Industries Ltd.,
Published by
Business Wire
14 Jun 11 Teva Signs $4 Billion Syndicated Credit Facilities Teva Pharmaceutical Industries Ltd.,
Published by
Business Wire
06 Jun 11 Teva to Present at the Goldman Sachs 32nd Annual Global Healthcare Conference Teva Pharmaceutical Industries Ltd.,
Published by
Business Wire
06 Jun 11 Teva Announces Successful Results of Phase III Study of Its Long-Acting G-CSF Product (Lipegfilgrastim) in Breast Cancer Patients Teva Pharmaceutical Industries Ltd.,
Published by
Business Wire
02 Jun 11 Teva Completes Enrollment in Phase III Multiple Sclerosis Trial Evaluating Glatiramer Acetate Three Times Weekly Teva Pharmaceutical Industries Ltd.,
Published by
Business Wire
02 Jun 11 Teva Announces Launch of Generic Aricept® Tablets in the United States Teva Pharmaceutical Industries Ltd.,
Published by
Business Wire
01 Jun 11 Teva and Pfizer Settle Generic Neurontin® Litigation Teva Pharmaceutical Industries Ltd.,
Published by
Business Wire
31 May 11 Teva Announces Data on Granulocyte Colony Stimulating Factor Compounds for the Prevention of Chemotherapy-Induced Neutropenia in Breast Cancer Patients Teva Pharmaceutical Industries Ltd.,
Published by
Business Wire
27 May 11 Teva Announces Approval of Generic Combivir Tablets: Launch Expected in Fourth Quarter 2011 Teva Pharmaceutical Industries Ltd.,
Published by
Business Wire
19 May 11 Teva and OncoGenex to Present Data on Custirsen in Prostate Cancer at the 2011 ASCO Annual Meeting Teva Pharmaceutical Industries Ltd.,
Published by
Business Wire
17 May 11 Teva and CureTech Announce Positive Phase II Data from CT-011, an Investigational Antibody in Diffuse Large B Cell Lymphoma Teva Pharmaceutical Industries Ltd.,
Published by
Business Wire
16 May 11 Teva to Acquire Taiyo Teva Pharmaceutical Industries Ltd.,
Published by
Business Wire
03 May 11 Teva to Present at the Deutsche Bank 36th Annual Health Care Conference Teva Pharmaceutical Industries Ltd.,
Published by
Business Wire
02 May 11 Teva to Acquire Cephalon in $6.8 Billion Transaction Teva Pharmaceutical Industries Ltd.,
Published by
Business Wire
22 Apr 11 Teva Pharmaceutical Industries Ltd. Makes Statement on DEFINE Study Results Teva Pharmaceutical Industries Ltd.,
Published by
Business Wire
21 Apr 11 Teva to Report First Quarter 2011 Financial Results on May 11, 2011 Teva Pharmaceutical Industries Ltd.,
Published by
Business Wire
14 Apr 11 New Study Demonstrated Significant Reduction in Annualized Relapse Rate and Halting of Disability Progression in MS Patients Switching To Copaxone® Teva Pharmaceutical Industries Ltd.,
Published by
Business Wire
12 Apr 11 Oral Laquinimod for Multiple Sclerosis Treatment Significantly Reduced Disease Activity and Disability Progression While Providing Good Safety and Tolerability Teva Pharmaceutical Industries Ltd.,
Published by
Business Wire
11 Apr 11 Teva Announces Presentation of New Data on Multiple Sclerosis and Parkinson’s Disease Treatments at 2011 American Academy of Neurology Annual Meeting Teva Pharmaceutical Industries Ltd.,
Published by
Business Wire
09 Apr 11 Teva Announces Webcast on Results from Phase III ALLEGRO Study of Oral Laquinimod in Multiple Sclerosis Teva Pharmaceutical Industries Ltd.,
Published by
Business Wire
06 Apr 11 Teva and OncoGenex Present Preclinical Data on the Activity of its Antisense Compound Custirsen (OGX-011/TV-1011) at the American Association of Cancer Research (AACR) Annual Meeting 2011 Teva Pharmaceutical Industries Ltd.,
Published by
Business Wire
24 Mar 11 The Procter & Gamble Company and Teva Pharmaceutical Industries Form Consumer Health Care Partnership Teva Pharmaceutical Industries Ltd.,
Published by
Business Wire
Advertising